June 7, 2021

Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients with COVID-19

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• Treatment with monoclonal antibody (mAb) therapy, including casirivimab/imdevimab and bamlanivimab, was associated with a significant reduction in the frequency of hospitalization compared to controls not receiving mAb treatment (1.7% vs. 24%) in a retrospective study of 617 outpatients with COVID-19 classified as high-risk (n = 175 received mAb). There were no COVID-19-related deaths in the mAb group vs. 12 (2.7%) among controls (p=0.024). The authors note that the mAb group was older, was more likely to be male, had more comorbidities, and a higher COVID-19 risk score.

Jenks et al. (June 6, 2021). Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients with COVID-19. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab522